KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neogenomics (NEO) Restructuring Costs (2022 - 2024)

Neogenomics filings provide 3 years of Restructuring Costs readings, the most recent being $2.4 million for Q1 2024.

  • On a quarterly basis, Restructuring Costs fell 48.8% to $2.4 million in Q1 2024 year-over-year; TTM through Mar 2024 was $8.8 million, a 4.33% decrease, with the full-year FY2024 number at $6.7 million, down 39.95% from a year prior.
  • Restructuring Costs hit $2.4 million in Q1 2024 for Neogenomics, up from $1.2 million in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $4.7 million in Q1 2023 to a low of $1.2 million in Q4 2023.
  • Median Restructuring Costs over the past 3 years was $2.7 million (2023), compared with a mean of $3.0 million.
  • Biggest five-year swings in Restructuring Costs: crashed 73.32% in 2023 and later tumbled 48.8% in 2024.
  • Neogenomics' Restructuring Costs stood at $4.5 million in 2022, then crashed by 73.32% to $1.2 million in 2023, then surged by 99.0% to $2.4 million in 2024.
  • The last three reported values for Restructuring Costs were $2.4 million (Q1 2024), $1.2 million (Q4 2023), and $2.1 million (Q3 2023) per Business Quant data.